Boston Scientific Corporation BSX recently announced receipt of the FDA’s approval for its TheraSphere Y-90 Glass Microspheres, which have been developed for the treatment of hepatocellular carcinoma ...
Nordion Launches a New and Improved TheraSphere® Website to Meet the Needs of Liver Cancer Physician
OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has ...
MU has launched its first clinical trial using reactor-made Eye90 microspheres to target inoperable liver tumors with ...
MILWAUKEE (WITI) -- A local man who built a multimedia empire from the ground up is now broadcasting the benefits of a relatively new cancer treatment. For more than 50 years, Vic Eliason has been a ...
The approval was based on data from the LEGACY study, a single-arm, retrospective trial that evaluated treatment with TheraSphere Y90 glass microspheres in 162 patients with unresectable ...
(RTTNews) - Boston Scientific Corp. (BSX) said that late-breaking data demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston ...
DECATUR - It comes in a vial smaller than a pinky finger, but this treatment available at Decatur Memorial Hospital has given hope to liver cancer patients seeking to prolong and improve their lives.
Boston Scientific Corporation BSX recently announced favorable study outcome of the TARGET study of its TheraSphere Y-90 Glass Microspheres (TheraSphere) therapy during a late-breaking clinical trial ...
MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a ...
NICE has issued guidance recommending the use of TheraSphere Y-90 Glass Microspheres, from Boston Scientific, as a treatment for patients with HCC. The National Institute for Health and Care ...
Nordion, Manufacturer of TheraSphere®, to Host Educational Symposium at the 2013 Gastrointestinal Ca
"Y-90 Glass Microspheres in HCC - What do we Know?" by Dr. Riad Salem, Interventional Oncologist, Northwestern University, Chicago, Illinois. Dr Salem will provide an overview of clinical utility of Y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results